Guocai’s "Contract Renewal Season": Is there a sharp increase in drug prices?

Contract renewal is an important issue for centralized drug procurement this year

"4+7" centralized drug procurement in cities takes 12 months from the result implementation date as a procurement cycle

The centralized drug procurement cycle in the alliance area is determined by the number of selected companies: the selected company does not exceed 2 (including) varieties, the procurement cycle is in principle 1 year; the selected company is the 3 varieties, and the procurement cycle is in principle 2 years

The procurement cycle rules for the second batch of centralized procurement and the third batch of centralized procurement are basically the same: the actual selected company in the country is a product, and the procurement cycle is in principle 1 year; the actual selected company in the country is a product of 2 or 3 companies, and the procurement In principle, the cycle is 2 years; the actual selected companies in the country are 4 or more varieties, and the procurement cycle is in principle 3 years

In the fourth batch of centralized procurement, the rules have been changed: if the number of companies actually selected in the country is 1 or 2, the procurement cycle is in principle 1 year; if the number of companies actually selected in the country is 3, the procurement cycle is in principle 2 years

In addition, the third batch of centralized procurement limits the procurement cycle of azacitidine injection, moxifloxacin sodium chloride injection, and concentrated solution for levetiracetam injection, which is 1 year in principle

In the fourth batch of centralized procurement, ambroxol injection, propofol medium/long-chain fat emulsion injection, ibuprofen injection, doxofylline injection, parecoxib injection, pantoprazole injection, bortezomib The purchase cycle of injections and bivalerudin for injection is limited to one year

(Click on the picture to enlarge)

In 2021, the alliance region will centrally purchase all products, the second batch of cephalexin capsules for centralized drug procurement organized by countries, the third batch of azacitidine for injection, moxifloxacin hydrochloride sodium chloride injection, and the third batch of centralized procurement for drugs organized by countries.

Among them, the products that have expired in 2021 include the first batch of nationally organized drug centralized procurement (including "4+7" and alliance expansion) paroxetine hydrochloride tablets, fosinopril sodium tablets, lisinopril tablets, chlorine Sartan potassium tablets, enalapril maleate tablets, levetiracetam tablets, imatinib mesylate tablets, montelukast sodium tablets, pemetrexed disodium for injection, flurbiprofen Ester injection, dexmedetomidine hydrochloride injection (11 products) and the second batch of cephalexin capsules for centralized drug procurement organized by the country

Direct renewal of most products

In most provinces, the contract renewal is directly renewed by the original national organization of the centralized drug procurement of the products that won the bid

There are also those who renew the contract and lower the price

  There are also provinces that reduce prices on the basis of the national centralized procurement prices

  On April 6th, at the drug centralized procurement policy explanation meeting held in Tianjin, for the renewal of centralized procurement products, if the product has been over-reviewed to more than 5, the competition is sufficient, and it is possible to renew the contract in a two-way linkage.

  In January 2021, Hubei issued the "National Organization of Centralized Drug Purchase Pilot Expansion (Hubei) Procurement Documents for Certain Varieties (HBSYXLHCG-2021-001)".

The price of cephalexin renewed bid soaring?

  The company selected for the centralized procurement of cephalexin capsules in the second batch of national organizations is Huabei Pharmaceutical Hebei Huamin Pharmaceutical, the specification is 0.
25g*60 capsules, the selected price is 5.
11 yuan, and the corresponding minimum unit is 0.
0852 yuan/capsule
.
In March 2021, Guangdong Province started the volume procurement of cephalexin drug alliance regions.
The alliance regions where cephalexin drugs participated in the reporting included Guangdong, Ningxia, Henan, Qinghai, Xinjiang, Xinjiang Corps, Yunnan, Guangxi, Guizhou, Jiangxi; Hainan Wei The quantity is reported but the selected results are implemented (the unselected will not be purchased online), and the procurement cycle is until June 30, 2023
.

  The Cephalexin Pharmaceutical Alliance is divided into 3 types of purchase orders
.
Cephalexin oral regular-release dosage forms, oral liquids, granules, and effervescent tablets that meet the consistency evaluation of generic drugs, original research drugs and reference preparations are included in the Class 1 A purchase order; meet the generics that have not passed the consistency evaluation Pharmaceutical cephalexin oral liquids, granules, and effervescent tablets are included in the Class 1 B purchase order
.
Cefalexin sustained-release and controlled-release dosage forms that have not passed the consistency evaluation are included in the Class 2 B purchase order
.
The selection results of Type 1 Purchase Order A/1 Type B Purchase Order/2 Type B Purchase Orders are formed by their respective bidding methods
.
The Pharmaceutical Alliance only limited the price of the planned selected cephalexin sustained-release controlled-release dosage form of the 2nd category B purchase order, and the price of 0.
25g per tablet should not be higher than 0.
42 yuan.
For oral regular-release dosage forms, it does not limit the price not higher than that of national sources
.

  On April 9th, Guangdong Pharmaceutical Trade Center issued a notice on publicizing the results of the planned selection of cephalexin drug alliance regional groups with volume purchases.
The oral regular-release dosage form of cephalexin was proposed to be selected by Hunan Kelun, and the price of the proposed selection was 0.
1489/capsule
.
The sustained and controlled release dosage form is proposed to be selected by Jiangsu Hausen, and the selected price is 0.
39 yuan
.
For the granular dosage form of cephalexin, because the lowest unit comparable price quoted by the company is 1.
2 times higher than the lowest price quoted by the manufacturer of oral regular-release dosage forms, there is no product to be selected
.

  Guangdong's cephalexin oral constant-release dosage form is expected to win a bid price higher than that of the national source, but in fact, Guangdong has referenced the price limit in Hebei
.
The price of oral normal-release dosage forms announced by Hebei is higher than that of Guangdong.
The price of Huabei Pharmaceutical Hebei Huamin Pharmaceutical Co.
, Ltd.
is planned to be 0.
1588 yuan, an increase of 86.
4%
.

  If the renewed bid of Guocai completely uses the original winning product and price, for the generic drug company, it is necessary to seize the time and find a way to win the bid on Guocai, otherwise the latecomers can only grab the remaining market
.

  If it is to join a new competitor to re-tender, is the national procurement price the "ceiling" for the maximum price? When multi-province alliance, should only the lowest price win the bid? Or do many provinces have won bids like Guocai? Many details are still worth considering
.